Poly (ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025

Description

PARP inhibitors (poly(ADP-ribose) polymerase inhibitors) are a class of drugs primarily used in cancer treatment. These medications work by inhibiting DNA repair in cancer cells, especially in cancers with BRCA mutations. They are commonly prescribed for ovarian and breast cancers and are typically taken orally. PARP inhibitors help lower the risk of cancer recurrence after chemotherapy, though they may cause side effects such as fatigue and low blood cell counts.

The main types of PARP inhibitors include olaparib, rucaparib, niraparib, talazoparib, and others. Olaparib is a well-known PARP inhibitor used to treat BRCA-mutated ovarian, breast, pancreatic, and prostate cancers by blocking DNA repair in cancer cells, which leads to cell death. These drugs are used for various indications, including ovarian cancer, breast cancer, prostate cancer, and pancreatic cancer. They are distributed via hospital pharmacies, retail pharmacies, and online platforms, and are utilized by hospitals, specialty clinics, research institutions, and other healthcare settings.

The poly (ADP-Ribose) polymerase (PARP) inhibitors market research report is one of a series of new reports from The Business Research Company that provides poly (ADP-Ribose) polymerase (PARP) inhibitors market statistics, including the poly (ADP-Ribose) polymerase (PARP) inhibitors industry global market size, regional shares, competitors with the poly (ADP-Ribose) polymerase (PARP) inhibitors market share, detailed poly (ADP-Ribose) polymerase (PARP) inhibitors market segments, market trends, and opportunities, and any further data you may need to thrive in the poly (ADP-Ribose) polymerase (PARP) inhibitors industry. This poly (ADP-Ribose) polymerase (PARP) inhibitors market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size has grown rapidly in recent years. It will grow from $6.53 billion in 2024 to $7.56 billion in 2025 at a compound annual growth rate (CAGR) of 15.7%. The growth during the historic period can be attributed to factors such as the rising incidence of cancer, increased genetic testing, higher success rates in clinical trials, expanding insurance coverage, and growth in cancer research.

The poly(ADP-ribose) polymerase (PARP) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $13.45 billion in 2029 at a compound annual growth rate (CAGR) of 15.5%. The growth during the forecast period can be attributed to factors such as the increasing production and supply of drugs, the rising prevalence of BRCA-mutated cancers, the growing incidence of breast cancer, the expanding use of monoclonal antibodies, and rising healthcare expenditure. Key trends in the forecast period include advancements in biomarker research, the use of combination therapies, the integration of artificial intelligence in drug development, progress in biomarker-driven therapies, and the development of next-generation PARP inhibitors.

The increasing prevalence of breast cancer is expected to drive the growth of the poly(ADP-ribose) polymerase (PARP) inhibitors market. Breast cancer is a disease where breast cells grow uncontrollably, forming malignant tumors that can spread to other areas of the body. Factors contributing to the rising prevalence include aging populations, lifestyle changes, genetic factors, hormonal imbalances, obesity, alcohol consumption, and exposure to environmental risks. PARP inhibitors help breast cancer patients by blocking the PARP enzyme's ability to repair DNA damage in cancer cells, causing cell death, particularly in tumors with BRCA1 or BRCA2 mutations. According to the National Breast Cancer Foundation, in January 2025, one in eight women in the United States will be diagnosed with breast cancer in their lifetime. In 2024, 310,720 women and 2,800 men were diagnosed with invasive breast cancer. As a result, the increasing prevalence of breast cancer is fueling the growth of the PARP inhibitors market.

Companies in the PARP inhibitors market are focused on advancing cancer treatments, such as anticancer medications, to target specific genetic mutations found in some cancers. These medicines work by inhibiting the growth of cancer cells, preventing their spread, or destroying them through various mechanisms, such as interfering with cell division, blocking proteins necessary for tumor growth, or stimulating the immune system to combat cancer. For instance, in March 2024, Zydus Lifesciences Limited, a pharmaceutical company based in India, launched IBYRA, a generic version of the PARP inhibitor olaparib. This drug offers an affordable and targeted treatment option for patients with HRD-positive and BRCA-positive cancers, significantly reducing treatment costs compared to the original medication.

In June 2023, Ariceum Therapeutics GmbH, a biotechnology company based in Germany, acquired Theragnostics Ltd. for an undisclosed amount. This acquisition aims to expand Ariceum Therapeutics' radiopharmaceutical pipeline by incorporating Theragnostics' next-generation PARP inhibitor radiation therapies, while also strengthening its U.S. operations. Theragnostics Ltd, a U.K.-based biopharmaceutical company, specializes in developing radio-labeled PARP inhibitors.

Major players in the poly(ADP-ribose) polymerase (PARP) inhibitors market are Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Merck & Co. Inc., Bayer AG, AstraZeneca plc, Bristol-Myers Squibb Company, GSK plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim, Vertex Pharmaceuticals Inc., Jiangsu Hengrui Pharmaceuticals Co. Ltd., BeiGene LTD, Karyopharm Therapeutics Inc., Clovis Oncology Inc., Repare Therapeutics Inc., Ribon Therapeutics, Artios Pharma, IMPACT Therapeutics Inc., BiPar Sciences Inc., and Allarity Therapeutics Inc.

North America was the largest region in the poly(ADP-ribose) polymerase (PARP) inhibitors market in 2024. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in poly(ADP-ribose) polymerase (PARP) inhibitors report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the poly(ADP-ribose) polymerase (PARP) inhibitors market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The poly(ADP-ribose) polymerase (PARP) inhibitors market consists of sales of rubraca, zejula, and talzenna. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on poly(adp-ribose) polymerase (parp) inhibitors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for poly(adp-ribose) polymerase (parp) inhibitors ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The poly(adp-ribose) polymerase (parp) inhibitors market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Olaparib; Rucaparib; Niraparib; Talazoparib; Other Types
2) By Indication: Ovarian Cancer; Breast Cancer; Prostate Cancer; Pancreatic Cancer
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
4) By End-User: Hospitals; Specialty Clinics; Research Institutions; Other End-Users
Subsegments:
1) By Olaparib: BRCA-Mutated Cancers; HRD-Positive Cancers; Maintenance Therapy
2) By Rucaparib: Ovarian Cancer; Prostate Cancer; Pancreatic Cancer
3) By Niraparib: First-Line Treatment; Recurrent Cancer Treatment; Late-Stage Cancer
4) By Talazoparib: Breast Cancer; Germline BRCA-Mutated Tumors; Neoadjuvant Or Adjuvant Therapy
5) By Other Types: Emerging PARP Inhibitors; Investigational Therapies; Novel Combinations
Companies Mentioned: Pfizer Inc.; Johnson & Johnson Services Inc.; AbbVie Inc.; Merck & Co. Inc.; Bayer AG
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery format: PDF, Word and Excel Data Dashboard.

Product Code: r34666

1. Executive Summary

2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Characteristics

3. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Trends And Strategies

4. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Growth Analysis And Strategic Analysis Framework

5.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Growth Rate Analysis
5.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Total Addressable Market (TAM)

6. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Segmentation

6.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Olaparib
Rucaparib
Niraparib
Talazoparib
Other Types
6.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ovarian Cancer
Breast Cancer
Prostate Cancer
Pancreatic Cancer
6.3. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
6.4. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Specialty Clinics
Research Institutions
Other End-Users
6.5. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Olaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
BRCA-Mutated Cancers
HRD-Positive Cancers
Maintenance Therapy
6.6. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Rucaparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Ovarian Cancer
Prostate Cancer
Pancreatic Cancer
6.7. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Niraparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
First-Line Treatment
Recurrent Cancer Treatment
Late-Stage Cancer
6.8. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Talazoparib, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Breast Cancer
Germline BRCA-Mutated Tumors
Neoadjuvant Or Adjuvant Therapy
6.9. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Emerging PARP Inhibitors
Investigational Therapies
Novel Combinations

7. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Regional And Country Analysis

7.1. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

8.1. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

9.1. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
9.2. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

10.1. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

11.1. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
11.2. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

12.1. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

13.1. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

14.1. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
14.2. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

15.1. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
15.2. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

16.1. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

17.1. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

18.1. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

19.1. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

20.1. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

21.1. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
21.2. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

22.1. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

23.1. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
23.2. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

24.1. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
24.2. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

25.1. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
25.2. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

26.1. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
26.2. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

27.1. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

28.1. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
28.2. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

29.1. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Overview
29.2. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Indication, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape And Company Profiles

30.1. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Landscape
30.2. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Johnson & Johnson Services Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Bayer AG Overview, Products and Services, Strategy and Financial Analysis

31. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Other Major And Innovative Companies

31.1. AstraZeneca plc
31.2. Bristol-Myers Squibb Company
31.3. GSK plc
31.4. Takeda Pharmaceutical Company Limited
31.5. Boehringer Ingelheim
31.6. Vertex Pharmaceuticals Inc.
31.7. Jiangsu Hengrui Pharmaceuticals Co. Ltd.
31.8. BeiGene LTD
31.9. Karyopharm Therapeutics Inc.
31.10. Clovis Oncology Inc.
31.11. Repare Therapeutics Inc.
31.12. Ribon Therapeutics
31.13. Artios Pharma
31.14. IMPACT Therapeutics Inc.
31.15. BiPar Sciences Inc.

32. Global Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

34. Recent Developments In The Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market

35. Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market High Potential Countries, Segments and Strategies

35.1 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Countries Offering Most New Opportunities
35.2 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Segments Offering Most New Opportunities
35.3 Poly(ADP-Ribose) Polymerase (PARP) Inhibitors Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer